AVX 901

Drug Profile

AVX 901

Alternative Names: AVX901; DUKE-002-VRP; HER2 ECDTM VRP; HER2 VRP; HUHER2-ECD+TM; VRP HER2 ECDTM

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AlphaVax
  • Developer AlphaVax; Duke University
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IM, Injection)
  • 02 Mar 2017 AlphaVax and Duke University complete a phase I trial for Breast cancer (Second-line therapy or greater, Late-stage disease, metastatic-disease) in USA (AlphaVax pipeline, March 2017) before March 2017
  • 31 Mar 2012 Phase-I clinical trials for Breast cancer (Second-line therapy or greater, Late-stage disease, metastatic-disease) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top